Dual GIP / GLP-1 receptor agonist
Tirzepatide
Also known as Mounjaro, Zepbound
FDA-approved drugThe first approved medicine that activates both the GIP and GLP-1 receptors.
Evidence
FDA-approved drug
Regulatory status
Prescription drug. FDA-approved for specific indications.
Class
Dual GIP / GLP-1 receptor agonist
What it is
Tirzepatide is a single peptide that acts on two incretin hormone receptors, GIP and GLP-1. Both are involved in insulin release and appetite signaling.
What the research shows
- Studied in the SURPASS (type 2 diabetes) and SURMOUNT (weight management) human trial programs.
- FDA-approved brands cover type 2 diabetes, chronic weight management, and obstructive sleep apnea in adults with obesity.
- Gastrointestinal effects are the most commonly reported side effects in trials.
Read the published research on PubMed →
Researched for
Tirzepatide is a prescription medicine approved only for specific uses. A licensed provider decides whether it is appropriate for you.
Educational content, not medical advice. This page does not recommend or dose any substance.
Related peptides
GLP-1 receptor agonist
Semaglutide
A GLP-1 receptor agonist and one of the most studied peptide medicines in the world.
FDA-approved drugTriple GIP / GLP-1 / glucagon receptor agonistRetatrutide
An investigational "triple agonist" currently in late-stage clinical trials.
Human clinical trialsLong-acting amylin analogCagrilintide
An amylin analog being studied alone and in combination with semaglutide.
Human clinical trials